By apyxmedical In 2022 Shareholder News, J-Plasma, RenuvionPosted May 26, 2022APYX MEDICAL CORPORATION RECEIVES FDA 510(K) CLEARANCE FOR THE USE OF RENUVION COSMETIC TECHNOLOGY IN DERMAL RESURFACING PROCEDURES READ MORE
By apyxmedical In 2022 Shareholder News, J-Plasma, RenuvionPosted May 25, 2022APYX MEDICAL CORPORATION TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES IN JUNE READ MORE
By apyxmedical In 2022 Shareholder News, J-Plasma, RenuvionPosted May 12, 2022APYX MEDICAL CORPORATION REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND UPDATES FULL YEAR 2022 FINANCIAL OUTLOOK READ MORE
By apyxmedical In 2022 Shareholder News, J-Plasma, RenuvionPosted April 4, 2022APYX MEDICAL CORPORATION TO RELEASE FIRST QUARTER OF FISCAL YEAR 2022 FINANCIAL RESULTS ON MAY 12, 2022 READ MORE
By apyxmedical In 2022 Shareholder News, J-Plasma, RenuvionPosted April 4, 2022APYX MEDICAL CORPORATION ANNOUNCES FDA 510(K) SUBMISSION WITH CLINICAL STUDY SUPPORT FOR THE USE OF THE RENUVION APR HANDPIECE FOR AESTHETIC PROCEDURES TO IMPROVE APPEARANCE OF LAX SKIN READ MORE
By apyxmedical In 2021 Shareholder News, 2022 Shareholder News, J-Plasma, RenuvionPosted March 17, 2022APYX MEDICAL CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS; INTRODUCES FULL YEAR 2022 FINANCIAL OUTLOOK READ MORE
By apyxmedical In 2022 Shareholder News, J-Plasma, RenuvionPosted March 14, 2022APYX MEDICAL CORPORATION NOTIFIED OF PENDING FDA MEDICAL DEVICE SAFETY COMMUNICATION RELATED TO ITS ADVANCED ENERGY PRODUCTS READ MORE
By apyxmedical In 2022 Shareholder News, J-Plasma, RenuvionPosted February 17, 2022APYX MEDICAL CORPORATION ANNOUNCES PEER-REVIEWED PUBLICATION FEATURING RESULTS FROM THE U.S. IDE CLINICAL STUDY EVALUATING THE RENUVION DERMAL HANDPIECE USING APYX’S HELIUM PLASMA TECHNOLOGY FOR DERMAL RESURFACING PROCEDURES READ MORE
